NCT06958627

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 964 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

Conditions

• HER2 Positive Breast Cancer
• Pyrotinib Treatment

Interventions

Type	Name	Description
DRUG	pyrotinib	Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.

Timeline

• Start date: 2024-04-30
• Primary completion: 2025-04-30
• Completion: 2027-04-30
• First posted: 2025-05-06
• Last updated: 2025-05-06

Locations

1 site across 1 country: China